The global Human Growth Hormone market gathered revenue around USD 5.9 Billion in 2020 and market is set to grow USD 9.1 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 10.7% during the prediction period 2021 to 2027.
-Market%C2%A0Size-2020-to-2027.jpg "Human Growth Hormone (hGH) Market Size 2020 to 2027")
Growth Factors:
The market Factors such as investments by market players, the presence of a strong pipeline, extensive R&D activities, robust product portfolio, and increasing government initiatives are expected to significantly drive the market.
Human growth hormone (HGH), also known as somatotropin, is a peptide hormone responsible for growth stimulation, cell reproduction, and cell regeneration in humans and is hence important for human development. Growth hormone (GH) deficiency in humans is caused when the pituitary gland does not synthesize enough concentration of hGH. This deficiency in humans is treated by administering recombinant human growth hormone by subcutaneous injection. Various genetic disorders, including Prader-Willi syndrome and Turner syndrome, may also cause growth hormone deficiency in humans, leading to delayed puberty and shorter-than-average height.
Robust product pipeline and extensive R&D activities for the development of novel growth hormone therapies are expected to be the major factors driving the market for human growth hormones. For instance, in September 2019, Novo Nordisk presented Phase II clinical trial data of its investigational GH therapy, Somapacitan, indicated for the treatment of pediatric growth hormone deficiency. In addition, in May 2020, Ascendis Pharma A/S published results from the Phase III clinical trial of its TransCon hGH, indicated for pediatric growth hormone deficiency. Similarly, various key players including Teva Pharmaceutical Industries, Ltd.; OPKO Health, Inc.; Eli Lilly and Company; Ferring Pharmaceuticals; Sanofi S.A.; and LG Life Sciences are involved in R&D activities for the development of novel human growth hormone therapies.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Human Growth Hormone market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Human Growth Hormone market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
Report Coverage
| Report Scope | Details |
| Market Size | USD 9.1 Billion by 2027 |
| Growth Rate | CAR 10.7% From 2021 to 2027 |
| Base Year | 2020 |
| Forecast Period | 2021 to 2027 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Segments Covered | Application, Route of Administration, Distribution Channel and Region |
| Report coverage | Growth Factors, Revenue Status, Competitive Landscape, and Future Trends |
| Companies Mentioned | Novo Nordisk, Merck & Co., Eli Lilly & Company, Pfizer Inc., Teva Pharmaceutical Industries, Novartis AG, Anhui Anke Biotechnology (Group) Co., Ltd., Roche, Ipsen, and Ferring BV. |
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Human Growth Hormone market Report empowers readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
Human Growth Hormone Market Segmentation analysis:
The human growth hormone market is segmented on the basis of application, route of administration, distribution channel, and region. On the basis of application, the market is divided into Growth hormone deficiency, Prader-willi syndrome, Turner syndrome, Small for gestational age (SGA), and Others. On the basis of route of administration, the market is divided into oral, intravenous, intramuscular, and subcutaneous. On the basis of distribution channel, the market is fragmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Regional analysis:
North America is estimated to account for the largest share owing to factors such as favorable reimbursement scenario, established healthcare infrastructure, significant government initiatives, and growing healthcare awareness. Furthermore, increased access to novel drugs due to the presence of key players in the region supports the North American market. Pfizer, Inc.; Eli Lilly and Company; and Genentech, Inc. are some U.S.-based key players that offer a wide range of human GH therapies in the region.
Asia Pacific is projected to register a significant CAGR over the forecast period. Key players focus on gaining a major market share in potential countries of the Asia Pacific such as Japan and China by gaining approval and the launch of novel products. For instance, in March 2017, Novo Nordisk A/S, a Denmark-based pharmaceutical company, initiated the phase III clinical trial of its HGH somapacitan, indicated for the treatment of adult growth hormone deficiency, in Japan.
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Some of the prominent players in the Human Growth Hormone Market include: Novo Nordisk, Merck & Co., Eli Lilly & Company, Pfizer Inc., Teva Pharmaceutical Industries, Novartis AG, Anhui Anke Biotechnology (Group) Co., Ltd., Roche, Ipsen, and Ferring BV.
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
Market Segments
By Application
By Route of Administration
By Distribution Channel
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Highlights of the Report:
Research Methodology
In the study, a unique research methodology is utilized to conduct extensive research on the growth of the Human Growth Hormone market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the Human Growth Hormone market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes the projections on the growth prospects of the Human Growth Hormone markets more accurate and reliable.
Secondary Research
It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.
The secondary research sources referred in the process are as follows:
Primary Research
Primary research includes face-to face interviews, online surveys, and telephonic interviews.
Industry participants involved in this research study include:
Key Points Covered in Human Growth Hormone market Study:
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers